[go: up one dir, main page]

WO2005103052A8 - Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof - Google Patents

Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Info

Publication number
WO2005103052A8
WO2005103052A8 PCT/IB2005/000991 IB2005000991W WO2005103052A8 WO 2005103052 A8 WO2005103052 A8 WO 2005103052A8 IB 2005000991 W IB2005000991 W IB 2005000991W WO 2005103052 A8 WO2005103052 A8 WO 2005103052A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolo
pyrimidin
cannabinoid
mediation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/000991
Other languages
French (fr)
Other versions
WO2005103052A1 (en
Inventor
David Andrew Griffith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2005103052A1 publication Critical patent/WO2005103052A1/en
Publication of WO2005103052A8 publication Critical patent/WO2005103052A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The compounds of Formula (I) and (II) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.
PCT/IB2005/000991 2004-04-21 2005-04-11 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof Ceased WO2005103052A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56464804P 2004-04-21 2004-04-21
US60/564,648 2004-04-21

Publications (2)

Publication Number Publication Date
WO2005103052A1 WO2005103052A1 (en) 2005-11-03
WO2005103052A8 true WO2005103052A8 (en) 2006-04-13

Family

ID=34963817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000991 Ceased WO2005103052A1 (en) 2004-04-21 2005-04-11 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2005103052A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503439B2 (en) 2023-04-21 2025-12-23 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
ATE452890T1 (en) 2003-11-04 2010-01-15 Merck & Co Inc SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES
KR20070089151A (en) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 New uses of cannabinoids
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
JP4847275B2 (en) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 Pyrazolo [1,5-a] pyrimidine compounds
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
TWI419889B (en) * 2006-07-05 2013-12-21 Mitsubishi Tanabe Pharma Corp A pyrazolo [1,5-a] pyrimidine compound
AR061793A1 (en) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION
JP4837701B2 (en) * 2007-04-20 2011-12-14 田辺三菱製薬株式会社 Pharmaceutical composition
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
MX390277B (en) 2016-08-31 2025-03-20 Servier Lab INHIBITORS OF CELLULAR METABOLIC PROCESSES.
CN112921405B (en) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 Method for synthesizing On-DNA pyrazolo [1,5-a ] pyrimidine compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503439B2 (en) 2023-04-21 2025-12-23 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Also Published As

Publication number Publication date
WO2005103052A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
MXPA05007562A (en) Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands.
CA2515596A1 (en) Cannabinoid receptor ligands and uses thereof
CA2503900A1 (en) Purine compounds and use thereof as cannabinoid receptor ligands
MXPA05013282A (en) Pyrimidine derivatives as cannabinoid receptor ligands.
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
MXPA05013294A (en) Cannabinoid receptor ligands and uses thereof.
MA29437B1 (en) IMIDAZOPYRIDAZINE COMPOUND
NO20053955D0 (en) Pyrazolo [1,5-A] pyrimidine derivatives
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
TW200508235A (en) Substituted hexahydropyrazino[1, 2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments
WO2004112719A3 (en) Chemical compounds
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
PL377660A1 (en) Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
UA93043C2 (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
DE60206946D1 (en) SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO [1,2-A] PYRIMIDIN-4-ON- AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO [1,2-A] PYRIMIDIN-5 (1H) ON DERIVATIVES AGAINST NEURODEEGENERATIVE DISEASES
TW200745121A (en) Chemical compound
WO2005103052A8 (en) Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
ATE512968T1 (en) 1,2,3,4-TETRAHYDROPYRROLO(1,2-A)PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO(1,2-A)-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
WO2005007083A3 (en) Chemical compounds
AP2006003539A0 (en) 5-halogeno-[1,2,4]triazolo[1,5-A] pyrimidines for combating animal pests.
WO2006044753A3 (en) Chemical compounds
DK1742950T3 (en) The pyrazolo [4,3-d] pyrimidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase